Infinata’s BioPharm Insight to Moderate Webinar with PwC Deals Team Executives on Current and Future Trends in Pharma M&A

Share Article

Award-winning journalist, Kimberly Ha, to draw practical advice and strategies from top pharmaceutical industry deal makers.

BioPharm Insight Global Editor Kimberly Ha will moderate a webinar with PwC Deals executives to discuss current and future trends in pharmaceutical industry M&A on October 30 at 10 a.m. ET.

BioPharm Insight is part of Infinata, a Financial Times Group company, and a leading provider of business intelligence solutions which also include BioPharm Clinical™, High Net Worth Insight™ and wealthmonitor™.

PwC US helps organizations and individuals create the value they're looking for. PwC’s Deals practitioners help corporate and private equity executives navigate transactions to increase value and returns.

Joining Kimberly will be:

Dimitri Drone, PwC Pharma and Life Sciences Deals Leader – Dimitri is the leader of PwC’s Deals business for the Pharmaceutical and Life Sciences sector. Dimitri advises corporate and private equity clients on the structuring of complex merger & acquisition transactions, alliances, partnerships and joint ventures, as well as minority investments to address financial reporting, corporate finance, and valuation issues. In addition, he is a leading advisor within the Firm to clients on valuation principles, methodologies and critical assumptions employed in various business enterprise, intangible asset and security valuation exercises across the spectrum of life science industries, including pharmaceuticals, biotech, medical device, diagnostics, generics, consumer, animal health and contract research organizations. Clients range from start-up biotech and medical device companies to the largest global life science companies.

James Woods, PwC Director, Valuation Practice – James is a leader in the Deals Pharmaceutical and Life Sciences sector practice. He has over 10 years of experience in valuation analysis and financial advisory work, including valuations of business enterprises, intangible assets and debt and derivative securities. James has extensive experience working with companies in the life sciences industry as well as transaction experience in the consumer and industrial and technology sectors. James has performed numerous business and intangible asset valuations for a variety of purposes, including financial and tax reporting, corporate restructurings, mergers and acquisitions, divestitures and corporate strategy.

Kimberly Ha is an award-winning biopharmaceutical industry journalist and editor. She launched BioPharm Insight's editorial team in 2007. Kimberly began her career as a financial journalist in Hong Kong specializing in healthcare M&A, and previously was the lead sector specialist at Mergermarket, a division of the Financial Times Group. She is a sought-after panelist and moderator at major healthcare investor conferences and events. A member of the Galien Foundation Advisory Board, Kimberly has received fellowships from organizations including the National Press Foundation, the UN Foundation for Global Vaccines, and the Association of Health Care Journalists.

Last month, Kimberly Ha moderated a panel to discuss challenges and opportunities in funding drug development at the US-Japan Health Sciences Dialogue. This month, she will moderate a panel on investment strategies for early stage companies at the Life Sciences Summit.

Register for this webinar.

About BioPharm Insight
BioPharm Insight is the definitive guide to the global biopharma community. BioPharm Insight provides subscribers with an information edge by combining the most comprehensive real-time database of companies, drugs, contacts, M&A and licensing deals, forecasts and clinical trial data with proprietary forward-looking intelligence uncovered by an independent team of investigative journalists months or even years before it breaks in mainstream media. To learn more, visit

About Infinata, Inc.
Infinata provides personalized technology solutions to turn information into insight. Services include a comprehensive BioPharm Solutions Suite, unique Wealth Prospecting tools and innovative Custom Data Services. Infinata is a part of Mergermarket, a Financial Times Group company and a division of Pearson plc. To learn more, visit

Business Inquiries: Holly Burke, hburke(at)infinata(dot)com, 781-619-0131
Media Inquiries: Brenda Nashawaty, Brenda(at)nashawaty(dot)com, 617-688-3253

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Holly Burke
+1 (781) 619-0131
Email >
Visit website